Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Current Taxes (2018 - 2022)

Historic Current Taxes for Regenxbio (RGNX) over the last 5 years, with Q1 2022 value amounting to $12.7 million.

  • Regenxbio's Current Taxes rose 21640.45% to $12.7 million in Q1 2022 from the same period last year, while for Mar 2022 it was $12.7 million, marking a year-over-year increase of 21640.45%. This contributed to the annual value of $11.3 million for FY2021, which is 26124.4% up from last year.
  • As of Q1 2022, Regenxbio's Current Taxes stood at $12.7 million, which was up 21640.45% from $11.3 million recorded in Q4 2021.
  • In the past 5 years, Regenxbio's Current Taxes registered a high of $12.7 million during Q1 2022, and its lowest value of $508000.0 during Q3 2019.
  • In the last 5 years, Regenxbio's Current Taxes had a median value of $1.8 million in 2018 and averaged $3.8 million.
  • As far as peak fluctuations go, Regenxbio's Current Taxes tumbled by 7687.58% in 2019, and later skyrocketed by 26124.4% in 2021.
  • Over the past 5 years, Regenxbio's Current Taxes (Quarter) stood at $726000.0 in 2018, then tumbled by 30.03% to $508000.0 in 2019, then surged by 517.13% to $3.1 million in 2020, then skyrocketed by 261.24% to $11.3 million in 2021, then rose by 11.89% to $12.7 million in 2022.
  • Its Current Taxes was $12.7 million in Q1 2022, compared to $11.3 million in Q4 2021 and $4.0 million in Q1 2021.